Cisplatin, an effective antineoplastic drug used in the treatment of many cancers, has
ototoxic potential, thus placing cancer patients, receiving this treatment, at risk of hearing …

In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment
suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) …

Context The most common adverse effects from neurotoxic chemotherapy are chemotherapy-
induced neuropathy (CIPN), hearing loss, and tinnitus. Although associations between …

Background Cisplatin is an effective chemotherapy agent against several pediatric
malignancies. One of its side effects is irreversible sensorineural hearing damage that is …

Ototoxicity is a debilitating side effect of platinating agents with substantial interpatient
variability. We sought to evaluate the association of thiopurine S‐methyltransferase (TPMT) …

Replication of findings in clinical pharmacogenetic studies is essential but often neglected.
The observation that TPMT and COMT genotypes, in combination with ABCC3 genotype …

Simple Summary Chemotherapy-induced peripheral neuropathy (CIPN) is a common
debilitating complication of treatment with platinum-based compounds and taxanes. CIPN is …

Objective: To identify any change in quality of life (QoL) caused by chemotherapy-induced
toxicities, such as hearing loss and tinnitus, to provide information in order to improve …

Evidence of significant hearing loss during the early days of use of cisplatin as a
chemotherapeutic agent in cancer patients has stimulated research into the causes and …

Ototoxicity and nephrotoxicity are potentially irreversible side effects of chemoradiotherapy
with cisplatin in locally advanced head and neck cancer (LAHNC) patients. Several …